Brailer Insists RHIOs Remain Important


Author: Neil Versel
SAN FRANCISCO The recent failure of several high-profile regional health information organizations (RHIOs) is not dampening the enthusiasm of the one-time champion of the RHIO, former national health-IT coordinator David Brailer.

“I think RHIOs are shaking out. No surprise,” Brailer said in an interview last week. “I think there’s a shakeout happening in health-IT quite broadly.”

Says Brailer, “I’ve viewed RHIOs essentially from the government as a political movement,” an effort to change health care from the bottom up. “It represented a visible statement of people not relying on Washington to tell them what to do. It represented an idea that health information is a broadly and profoundly decentralizing force, a democratizing force in health care.”

He says that RHIOs also stand for an “uprising” by people within communities who want to improve health care. “Health care change is about persistence. RHIOs are about persistence, and I don’t think they’re about a short-term win.”

Likewise, Brailer is not surprised that so many RHIOs are having difficulty finding a sustainable model including the one he helped start, the Santa Barbara County (Calif.) Care Data Exchange, which went under late last year.

“When you’re in an industry that penalizes efficiency and penalizes quality, if your primary purpose is efficiency and quality, it’s hard to create a business model,” Brailer says.

However, he remains bullish on health information exchange as a force for progress. “The very presence of RHIOs makes it more likely that positive change will happen, and that change will help RHIOs be sustained,” Brailer says.

“Keep trying, because these are moving in the right direction, and people don’t understand how close they are to tipping over some of these status-quo forces that have kept us from making progress,” he advises.

Though he left his job as national coordinator in May 2006 and cut his last government ties in May 2007 when he stepped down as co-chair of the American Health Information Community in May 2007, Brailer has remained attuned to happenings in health-IT, in part because of his new job. He now heads Health Evolution Partners, a private-equity firm that is managing $700 million in capital from the California Public Employees Retirement System, or CalPERS. (See “Brailer Leads New Venture Capital Firm.”)

Brailer recently went public with his investment strategy, saying that $500 million of the money will go toward late-stage startups and growth companies, $10 million to $80 million at a time. With the remaining $200 million, Health Evolution Partners will partner with other investors to support early-stage ventures. “We’re not going to do early-stage companies directly,” Brailer says.

“The opportunities and the sweet spot in health care investing right now is in these early-growth-stage companies, companies that are past proof-of-concept,” according to Brailer. “They need financial capital. They also need a lot of know-how. We bring both of them.”

He appeared last week at a San Francisco conference on user-generated technologies collectively known as “health 2.0,” where a good number of start-ups were chasing some of those millions. (See Inaugural Health 2.0 Conference is Harbinger of More to Come.”)

Brailer won’t be making direct investments in health 2.0 companies right away, since most are early-stage ventures. “I’m here to really get a sense about which venture partners we should work with in this space, what the companies are, because we will be doing things here, but, again, through partners, not directly,” he says.

Want to read more expert articles like this? Click here to subscribe to Digital HealthCare & Productivity.

 

Click here to log in.

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

thomson reuters image
Biomarkers: An Indispensible Addition to the Drug Development Toolkit
Examining the Potential of Biomarkers
Sponsored by Thomson Reuters

Biomarkers are becoming an essential part of clinical development. In this white paper, Thomson Reuters provides insight from experts in industry and academia, and explores the role of biomarkers as evaluative tools in improving clinical research and the challenges this presents.

Discover the potential of biomarkers to:

  • Improve decision making
  • Accelerate drug development
  • Reduce development costs


BlueArc_Scientific Data
Scientific Data Lifecycle Management: Preparing for Storage in an Uncertain Future
Sponsored by BlueArc

Managing vast and overwhelming streams of gene sequencing data today requires ultra-high performance systems and processes. With continued rapid advancement and improvements in gene sequencing, expect tomorrow’s instruments to output quantities of genomic information that will dwarf current levels. Help your organization maintain data control and prepare for the future of sequencing through this informative paper that discusses:

  • The information technology challenges of gene sequencing
  • “Intelligent” methods for data management and customization
  • System survival tips... Deciding what data to keep or delete
  • New tools to keep scientists ahead of impending data torrents


SAS Managed image
Managed Innovation, Assured Compliance
Developing, executing and managing the transformation, analysis and submission of clinical research data with SAS® Drug Development
Sponsored by SAS
Get better products to market faster. Download this white paper to discover the top ten challenges facing life science executives and how to overcome them. See how SAS Drug Development transforms clinical data into true innovation.


Life Science Webcasts & Podcasts

Presented by Trade Commission of Spain

Spain Biotech: An Engine for Economic Change 

TCS podcastDiscover how Spain is focusing on biotechnology to be an engine for economic change through gradual internationalization, development and technology transfer.

Regional governments are actively investing in public and private biology research and promoting the creation of knowledge-based companies. Spain’s human capital combined with aggressive investment in biotech research and infrastructure has led to the creation of bio-clusters.

Today, there are nearly 700 Spanish companies engaged in biotechnology, with almost 50 percent growth in funding devoted to research. In fact, spending on internal R & D in biotechnology has grown 46 percent and is close to 300 million Euros.

Access the podcast 

 



More Podcasts

Job Openings

saic_logo

MANAGER, SCIENTIFIC COMPUTING & PROGRAMMING
(Bioinformatics Manager)
SAIC-Frederick, Inc has an exciting opportunity for a Manager, Scientific Computing & Programming - Core Genoytyping Facility in Gaithersburg, Maryland.  In this role, you will lead the Bioinformatics & Analysis Group.
Master’s or equivalent required.  PhD preferred. Six years experience in development of scientific programs in high-performance computing environment including five years supporting scientific research in computational chemistry, biology, or genetics, & two years supervisory experience.  View complete job posting & apply: www.saic-frederick.com. Position #146945.

For reprints and/or copyright permission, please contact The YGS Group, 1808 Colonial Village Lane, Lancaster, PA;

(717) 399-1900 ext. 125, or via email to Ashley.Zander@theYGSgroup.com.